NCT04520750Phase 3Completed

VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita

Study sponsor: Palvella Therapeutics, Inc. · PVLA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2021-06-30Actual
Enrollment · participants36Actual
Source updated2024-08-29Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview